BridgeBio's founder saw biotech VCs exclusively funding high-risk "home run" platforms. He built a company to acquire therapies for smaller rare genetic diseases—"singles and doubles"—that were ignored. Aggregating these de-risks the portfolio and creates a major market opportunity.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Instead of relying on finding novel targets, a key strategy in neuropsychiatry is to revisit failed compounds that showed efficacy signals. Companies use modern chemistry and delivery to engineer solutions that separate efficacy from the historical liabilities that halted development, turning past failures into new opportunities.

Roivant's early success came from identifying and building companies around promising drug assets that were deemed non-strategic by large pharmaceutical firms. This approach capitalized on undervalued IP and focused execution, pre-dating the now-common trend of pharma spin-outs.

The ultimate vision is a dynamic marketplace where pharma companies routinely list their shelved assets. This "eBay for drug candidates" would allow interested parties—from biotechs to patient advocacy groups—to access information, assess opportunities, and bid on developing these assets, creating a systematic and efficient repurposing pipeline.

The strategy is to acquire biotech companies at valuations justified by a narrow clinical indication (e.g., premature ejaculation). The massive return comes from the "free option" of the much larger off-label consumer market (e.g., all men wanting to last longer) that is not priced in.

Developing drugs for rare diseases demands a hands-on, dedicated approach. Unlike mass-market trials, it involves deep partnerships with busy academic centers and requires a company culture entirely focused on the unique, high-touch challenges of the space.

The Priority Review Voucher (PRV) program creates a compelling business case for ultra-rare diseases. The voucher, sellable for over $100 million, can provide a significant return to investors on its own. This financial incentive is so strong that a company could theoretically give the resulting drug away for free and still be profitable.

A drug that is proven safe in humans but fails to show efficacy for its initial target is not a total loss. It's a de-risked asset with a known safety profile, making it a prime, low-risk candidate for repurposing into a new disease area, especially for rare diseases with orphan drug protections.